Viridian Therapeutics, Inc.

NASDAQ:VRDN

Biotechnology

Healthcare
$31.44 -0.88%

-$0.15 today

Market cap
$3.57B
Beta
0.90
P/E (TTM)
-4.7
EPS (TTM)
-$3.53
52W Low $13.18High $34.29

Volume 4.02M

Average 2.86M

Income Statement

Follow revenue through to earnings.

Revenue

$70.85M

FY 2025 · Annual

+23359.9% YoY

Operating Income

-$363.39M

FY 2025 · Annual

Net Income

-$342.60M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.96M1.77M314K302K70.85M
Cost of Revenue00000
Gross Profit2.96M1.77M314K302K70.85M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development56.89M100.89M159.77M238.25M338.93M
Selling, General & Admin25.81M35.18M95M61.08M95.32M
Operating Expenses82.69M136.08M254.76M299.34M434.24M
Depreciation & Amortization120K255K522K540K460K
EBITDA(79.29M)(129.13M)(235.37M)(266.36M)(337.19M)
EBITDA Margin-2676.0%-7287.4%-74957.0%-88199.7%-475.9%
Operating Income(79.73M)(134.3M)(254.45M)(299.04M)(363.4M)
Operating Margin-2690.8%-7579.2%-81035.0%-99018.2%-512.9%
Interest Income318K4.92M18.56M32.13M27.4M
Interest Expense3K486K1.85M3.05M4.95M
Other Income / Expenses315K4.43M16.72M29.09M20.79M
Income Before Tax(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Pre-Tax Margin-2680.2%-7329.2%-75711.5%-89387.1%-483.6%
Income Tax Expense00000
Net Income(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Net Margin-2680.2%-7329.2%-75711.5%-89387.1%-483.6%
EPS (Basic)(6.66)(3.91)(5.31)(3.98)(3.32)
EPS (Diluted)(6.66)(3.91)(5.31)(3.98)(3.32)
Weighted Avg Shares11.92M32.09M44.76M67.89M84.8M
Weighted Avg Shares (Diluted)11.92M32.09M44.76M67.89M84.8M

VRDN Earnings Waterfall · TTM

NASDAQ:VRDN · Revenue to Net Income

Key Ratios

EPS$-3.53
Gross Margin39.4%
Net Margin-52596.3%
P/E Ratio-8.0
P/S Ratio10293.9

Analysis

$71.1M of revenue converted into -$387.0M of net income for the selected period. Gross margin is 39.4% and net margin is -52596.3%, showing how much revenue survives after costs and taxes. EPS is $-3.53, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
4Statement of changes in beneficial ownershipAug 20, 2026

How much revenue does VRDN generate?

Viridian Therapeutics, Inc. (VRDN) reported $70.85M of revenue in fiscal 2025.

Is VRDN profitable?

Viridian Therapeutics, Inc. (VRDN) reported -$342.60M of net income, with a net margin of -483.6%.